The international market price of generic tenofovir, prequalified by WHO for hepatitis B virus infection, declined more than 85% from 2004 to 2016, according to recent MMWR data. Still, only one in six patients diagnosed with HBV infection worldwide received treatment in 2016.
, MD, PhD, medical epidemiologist from WHO’s department of HIV and the Global Hepatitis Program, and colleagues found that treatment coverage was low in low- and middle-income countries (LMICs), even though most these countries could legally procure generic versions of both WHO-recommended HBV medications, entecavir and tenofovir.
This activity is supported by an educational grant from ViiV Healthcare.
Zika Resource Center
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.